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Introduction {#sec1}
============

Protein secretion systems are used by bacteria to interact with other organisms and exploit the local environment ([@bib29]). Proteins transported by these systems shape the behavior of polymicrobial communities and interfere with eukaryotic cells. The type VI secretion system (T6SS) delivers effector proteins into both bacterial and eukaryotic targets in a contact-dependent manner ([@bib40], [@bib44]) and has been proposed to be involved in the acquisition of public goods such as metal ions ([@bib59], [@bib100], [@bib101]). Although the T6SS can manipulate signaling pathways and the cytoskeleton of eukaryotes ([@bib4], [@bib17], [@bib37]), it appears to be predominantly involved in bacterial antagonism, in which toxin delivery into neighboring cells elicits growth inhibition and cell death ([@bib2], [@bib36], [@bib61], [@bib90]).

The T6SS is a contractile injection system anchored in the bacterial envelope, evolutionarily related to bacteriophage tails ([@bib57], [@bib81]). A conformational change of the T6SS baseplate platform is thought to trigger the contraction of a cytoplasmic sheath, expelling a spear-like structure to puncture a target cell membrane ([@bib20], [@bib91], [@bib113]). The spear is composed of a stack of Hcp rings capped with a spike complex of a trimer of VgrG proteins and a PAAR protein tip ([@bib72], [@bib83], [@bib99]). The trimeric VgrG complex shares extensive structural homology with the bacteriophage gp27-gp5 tail spike, which also serves as a membrane puncturing device ([@bib35], [@bib57], [@bib81]). The spear is decorated with cargo effector proteins, often associating through non-covalent interactions with the structural components ([@bib20], [@bib46], [@bib99]). Besides these cargo effectors, effector domains can be fused to a Hcp, VgrG, or PAAR protein. Examples of these specialized effectors, also called evolved spear components, include the NAD(P)^+^-hydrolyzing toxin Tse6 from *Pseudomonas aeruginosa* or the peptidoglycan hydrolase extension of VgrG3^VC^ of *Vibrio cholerae* ([@bib10], [@bib36], [@bib115]).

*P. aeruginosa* possesses three T6SSs, designated H1-, H2-, and H3-T6SS ([@bib72]). Although the H1-T6SS is well characterized as an antibacterial weapon, our understanding of the effectors secreted by the H2-T6SS is still in its infancy. Two phospholipases, PldA and Tle4, are secreted by this system into both bacterial and eukaryotic cells and have consequently been designated trans-kingdom effectors ([@bib44], [@bib45]). In addition, the antibacterial nuclease effector TseT and the evolved VgrG2b have been linked to this system ([@bib11], [@bib92]). VgrG2b is involved in the internalization of *P. aeruginosa* PAO1 into epithelial cells, because uptake of a *vgrG2b* mutant is decreased versus the wild-type strain ([@bib92]). Infection of epithelial cells expressing *vgrG2b* displays enhanced internalization not only of wild-type *P. aeruginosa* but also of an H2-T6SS-deficient strain. Elements of the host cytoskeleton are co-opted for invasion, because chemical inhibition of actin and microtubule polymerization blocks bacterial uptake. Furthermore, interactome analysis of VgrG2b ectopically expressed in host cells identified components of the γ-tubulin ring complex (γTuRC) as binding partners of this evolved spike protein. Despite the microtubule network being implicated in *P. aeruginosa* invasion, the mechanism of this process remains to be understood.

In this study, we report that VgrG2b represents an evolved trans-kingdom T6SS effector. We provide evidence that VgrG2b is directly secreted by the H2-T6SS and that the VgrG2b C-terminal domain (VgrG2b~C-ter~) possesses antibacterial activity. We show that this domain, the structure of which we present in this work, is a member of a widespread family of metallopeptidases eliciting toxicity in the bacterial periplasm and that it can be neutralized by a cognate immunity protein. The toxicity of VgrG2b~C-ter~ results in profound morphological anomalies characterized by blebbing of the bacterial membrane at the site of septation, a phenotype reminiscent of inhibition of the cell division machinery by β-lactam antibiotics.

Results {#sec2}
=======

VgrG2b Is an Evolved VgrG Protein Secreted by the H2-T6SS {#sec2.1}
---------------------------------------------------------

VgrG2b is encoded in the *hcpC* locus with the hypothetical protein PA0261 and the effector-immunity module Tle3-Tli3 (type VI lipase effector 3-type VI lipase immunity 3) ([Figure 1](#fig1){ref-type="fig"}A), where Tle3 is a predicted phospholipase ([@bib6], [@bib116]). As such, it is not genetically linked to any T6SS core gene clusters. Beyond its canonical trimeric spike-forming region containing gp27- and gp5-like domains, VgrG2b harbors a C-terminal extension, rendering it an evolved VgrG protein ([Figure 1](#fig1){ref-type="fig"}B). VgrG2b also contains a DUF2345 domain, predicted to adopt a β-helical fold similar to the gp5-like domain ([Figure 1](#fig1){ref-type="fig"}C), which can be considered an extension of the spike region ([@bib92]). The C-terminal portion of the VgrG2b spike protein is predicted to function as a metallopeptidase because of the presence of a signature zinc-binding HEXXH motif ([Figure 1](#fig1){ref-type="fig"}B). Bioinformatic analysis of the linker region between the DUF2345 and the metallopeptidase domains reveals a transthyretin (TTR)-like fold, implicated in protein-protein interactions. Indeed, C-terminal TTR folds have been described in PAAR and VgrG proteins, with that of VgrG1 in enteroaggregative *Escherichia coli* empirically shown to be important in the delivery of the cargo effector Tle1 ([@bib30], [@bib99]).Figure 1H2-T6SS-Dependent Secretion of the Evolved VgrG2b(A) *vgrG2b* locus of *P. aeruginosa* PAO1. The *vgrG2b* gene is colored according to its domain architecture shown in (B). *PA0261*, shown in blue, is also characterized in this work. Scale bar represents 5 kb.(B) Schematic of the domain organization of the VgrG2b protein. The N-terminal region (yellow) forms the spike-like structure of the T6SS spear, composed of the gp27- and gp5-like domains and likely the DUF2345 domain. The TTR domain is a putative protein-protein interaction domain. The C-terminal domain has an HEXXH motif typically found in the catalytic site of metallopeptidases.(C) Model of the tertiary structure of the DUF2345 domain of the VgrG2b trimer, with the protomers depicted in red, yellow, and teal.(D) Immunoblot demonstrating secretion of VgrG2b by the H2-T6SS. Red arrows indicate the band corresponding to the VgrG2b protein to distinguish it from the non-specific bands recognized by the polyclonal antibody. Anti-RpoB recognizes the β subunit of RNA polymerase and is employed as a lysis control, while anti-LasB detects a secreted type II secretion system (T2SS) effector protein, used as a supernatant loading control. Image is representative of three independent experiments.Uncropped immunoblots and gels of all figures are provided in [Data S1](#mmc3){ref-type="supplementary-material"}.

A previous study determined that VgrG2b and the H2-T6SS are required in invasion of epithelial cells during infection, but no H2-T6SS-dependent secretion of VgrG2b was effectively demonstrated ([@bib92]). We have recently described *in vitro* conditions in which the H2-T6SS is active and established that the Hcp2 tail tube protein, encoded by at least one of the identical paralogs *hcpA*, *hcpB*, *hcpC*, and *hcp2* in *P. aeruginosa* PA14, is secreted by this system ([@bib2]). Here, we employed antibodies raised against peptides within the metallopeptidase domain of VgrG2b to probe for this spike protein in the supernatant of *P. aeruginosa* cultures grown in H2-T6SS-conducive conditions. VgrG2b and Hcp2 are detected in the extracellular milieu of the parental strain (PAO1Δ*rsmA*); however, deletion of the *tssE2* gene, encoding an H2-T6SS baseplate component, abolishes their secretion ([Figure 1](#fig1){ref-type="fig"}D). Complementation with *tssE2 in trans* partially restores secretion of VgrG2b and Hcp2.

Altogether, this confirms that VgrG2b is secreted in an H2-T6SS-dependent manner. Although the *H2-T6SS* locus of *P. aeruginosa* PAO1 lacks genes encoding the spike and tube proteins of the T6SS spear assembly, this result highlights that the H2-T6SS supports the secretion of several of distally encoded effectors ([@bib6], [@bib35]).

Crystal Structure of VgrG2b C-Terminal Effector Domain {#sec2.2}
------------------------------------------------------

Next, we purified VgrG2b~C-ter~ (residues 770--1,019) to initiate structural analysis. We solved the structure of VgrG2b~C-ter~, encompassing residues 833--1,019, using crystals of both the native and the selenomethionine-substituted forms with resolutions of 3.2 and 3.0 Å, respectively ([Figure 2](#fig2){ref-type="fig"}A). Two copies of VgrG2b~C-ter~ were found in the asymmetric unit of the crystal, which could be superimposed with a root-mean-square deviation (RMSD) of 0.1 Å ([Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}). In solution, however, the purified metallopeptidase domain exists predominantly as a monomer, as determined by size-exclusion chromatography-multi-angle laser light scattering (SEC-MALLS), with a dimeric species also present ([Figure S1](#mmc1){ref-type="supplementary-material"}A). It is likely that the physiologically relevant oligomerization state of the metallopeptidase domain is achieved only in the full-length VgrG2b protein.Figure 2Structure of the VgrG2b Metallopeptidase Domain(A) Cartoon representation of the metallopeptidase fold of the VgrG2b C-terminal domain. The zinc ion is modeled in the catalytic center as a gray sphere. Elements of secondary structure are labeled (α, α helix; β, β strand) and the three catalytic residues are shown as sticks. See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.(B) Comparison of the active site of the VgrG2b metallopeptidase domain (left) with that of angiotensin-converting enzyme 2 (right) from *Homo sapiens* (PDB: [3D0G](pdb:3D0G){#intref0055}). The coordinating residues of the gray zinc ion are labeled. In VgrG2b~C-ter~, H935, E936, and H939 form the catalytic triad, and E983 is the additional ligand; the corresponding residues in human angiotensin-converting enzyme 2 are H374, E375, H378, and E736, respectively.

The VgrG2b~C-ter~ protomer possesses a single domain composed of six α helices and three β strands ([Figure 2](#fig2){ref-type="fig"}A), forming a shallow bowl with multiple small loops. A PDB search using the DALI server identified several thermolysin-like metallopeptidases as structural homologs of the VgrG2b~C-ter~ effector domain ([@bib41]). One such metallopeptidase is human angiotensin-converting enzyme 2 (*Z* score: 5.0, C~α~ RMSD of 4.2 Å across 105 residues), with the active sites of these proteins displaying similar architectures ([Figure 2](#fig2){ref-type="fig"}B). Although metallopeptidases target diverse substrates, the overall core fold of three α helices (α2, α3, and α5) and two β strands (β2 and β3) is highly conserved and bears the classical HEXXH catalytic motif typical of these zinc-dependent enzymes, where X is any amino acid ([Figure 2](#fig2){ref-type="fig"}B).

Indeed, the conformations of the HEXXH residues in our structure are suggestive of metal ion coordination, and the geometry suggests that the electron density in the putative metal-binding site corresponds to a divalent cation such as zinc. To confirm that VgrG2b~C-ter~ binds zinc, we employed differential scanning fluorimetry to assess the thermodynamic stabilization of the metallopeptidase in the presence of zinc ions. The melting temperature of the domain increases from 46.3°C in the absence of zinc to a maximum of 55.1°C in the presence of an eight-fold excess of the metal ion ([Figure S1](#mmc1){ref-type="supplementary-material"}B), providing a strong indication of the binding of zinc to the metallopeptidase. The assigned zinc ion is coordinated by the two histidine residues of the catalytic triad and has a third glutamate ligand (E983) at the top of helix α5 ([Figure 2](#fig2){ref-type="fig"}B). These features permit classification of VgrG2b~C-ter~ as a thermolysin-like gluzincin within the MA(E) metallopeptidase subclan ([@bib82]).

VgrG2b~C-ter~ Is Part of a Wider Family of Metallopeptidase Effectors {#sec2.3}
---------------------------------------------------------------------

We assessed the prevalence of the VgrG2b~C-ter~ metallopeptidase domain by exploring its phylogenetic distribution. Homologous metallopeptidases were found throughout the proteobacterial phylum, especially in bacteria possessing a T6SS ([@bib58]) ([Figure 3](#fig3){ref-type="fig"}A). Intriguingly, the presence of VgrG2b~C-ter~-like proteins in *Sphingomonadaceae*, which rarely encode a T6SS, implies that this protein family may have a role beyond constituting a T6SS effector. Nevertheless, many orthologs are encoded within T6SS gene clusters and are classified as DUF4157 domain-containing putative metallopeptidases, found as both putative cargo and specialized effectors. For example, *Burkholderia pseudomallei* encodes an evolved VgrG with this metallopeptidase domain, similar to VgrG2b. Yet in *Collimonas* and *Alcanivorax* species, it is grafted as an extension of a PAAR protein. Finally, many members of the *Enterobacteriaceae* family code for this metallopeptidase as a putative T6SS cargo effector ([Figures 3](#fig3){ref-type="fig"}B and 3C), underscoring the modularity of T6SS effector proteins.Figure 3Phylogenetic Analysis of the VgrG2b Metallopeptidase Domain(A) Phylogenetic tree of 240 homologs of the VgrG2b metallopeptidase domain constructed using the maximum likelihood method. Clades are colored by bacterial family, and the branch denoting VgrG2b of *P. aeruginosa* is labeled with a red arrow. The scale represents the number of residue substitutions per site.(B) Schematic representation of the domain architecture of various VgrG2b metallopeptidase domain orthologs. The sequence logo shows the conservation of residues constituting the predicted HEXXH catalytic motif.(C) Diagram of genetic cassettes encoding VgrG2b metallopeptidase homologs (shown with an asterisk) found within T6SS loci. In each case, the gene encoding the putative metallopeptidase lies upstream of a small ORF. The VgrG2b~C-ter~ homolog in *B. thailandensis* is the evolved VgrG BTH_I2697; SARI_02727 of *S. arizonae* and ACIAD0053 of *Acinetobacter baylyi* are predicted cargo effectors, whereas in *Alcanivorax dieselolei*, B5T_02182 is a putative evolved PAAR protein.(D) Schematic of the genetic loci of the *vgrG2b* satellite islands of *P. aeruginosa* strains PAO1 and BL21. The site of a possible recombination event suggesting duplication of the *tle3-tli3* module within the 3′ end of *vgrG2b* in *P. aeruginosa* BL21 is shown by dotted lines. The gene encoding the VgrG2b~C-ter~ metallopeptidase is marked by an asterisk. Scale bar represents 5 kb.

Further analysis of the distribution of *vgrG2b* genes uncovered evidence for a remarkable recombination event in the *P. aeruginosa* BL21 strain, in which the *tle3-tli3* module is duplicated within the 3′ end of the *vgrG2b* gene ([Figure 3](#fig3){ref-type="fig"}D). This has given rise to a canonical *vgrG* gene encoding VgrG2b up to its TTR fold, with the metallopeptidase domain encoded by a separate open reading frame (ORF) downstream of the phospholipase effector-immunity locus. This genetic reorganization also implies that *vgrG* genes can acquire or lose their 3′ end through recombination, allowing the exchange of effector domains at the VgrG tip. This is reminiscent of observations concerning C-terminal toxin modules in systems such as contact-dependent growth inhibition (CDI) and Rhs proteins ([@bib86], [@bib112]). Overall, these *in silico* analyses suggest that VgrG2b~C-ter~ is frequently associated with proteobacterial T6SS loci and that its secretion can be achieved via various effector configurations.

VgrG2b-PA0261 Constitutes an Antibacterial Effector-Immunity Pair {#sec2.4}
-----------------------------------------------------------------

Our bioinformatic analysis of the genetic context of T6SS-associated VgrG2b~C-ter~ orthologs revealed intriguing synteny of this effector gene with a small ORF, often unannotated and encoded downstream, such as *PA0261* in *P. aeruginosa* ([Figure 1](#fig1){ref-type="fig"}A), *BTH_I2696* in *Burkholderia thailandensis*, *ACIAD0054* in *Acinetobacter baylyi*, *SARI_02726* in *Salmonella enterica* subsp. *arizonae*, or *B5T_02183* in *Alcanivorax dieselolei* ([Figure 3](#fig3){ref-type="fig"}C). The juxtaposition of these genes is invariable, prompting the hypothesis that *P. aeruginosa* VgrG2b~C-ter~ may constitute an antibacterial effector-immunity pair with the *PA0261* gene product. Indeed, T6SS effectors whose genes are systematically encoded in tandem with a small ORF are frequently found to exert antibacterial activity, with the adjacent gene encoding its cognate immunity protein ([@bib28], [@bib42], [@bib87]).

We engineered a strain lacking the *vgrG2b-PA0261* genes and placed it in competition with the parental strain under conditions in which the H2-T6SS is active. Whereas competition of the parent with itself results in competitive parity, the Δ*vgrG2bPA0261* strain exhibits a significant growth disadvantage ([Figure 4](#fig4){ref-type="fig"}A). VgrG2b is responsible for the advantage of the parental strain, because a Δ*vgrG2b* attacker no longer outcompetes the Δ*vgrG2bPA0261* prey. Importantly, the attacker and prey strains are isogenic; thus, the *vgrG2b-PA0261* module represents the sole difference between these strains. As such, the prey strain is immune to the action of all other T6SS toxins such as Tle3, encoded downstream of *PA0261* ([Figure 1](#fig1){ref-type="fig"}A). Deletion of *tssE2* in the attacker strain, rendering the H2-T6SS non-functional, restores competitive parity of the prey strain, confirming the H2-T6SS-dependent secretion of VgrG2b ([Figure 4](#fig4){ref-type="fig"}A), whereas complementation of *tssE2* on a plasmid partially restores the growth advantage of the attacker strain. Furthermore, a *P. aeruginosa* strain lacking the immunity gene exhibits a growth defect on solid media, but not in liquid culture, consistent with contact-dependent delivery by the H2-T6SS ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B).Figure 4VgrG2b~C-ter~ Is the Periplasmic Toxin of an Antibacterial Effector-Immunity Pair(A) Intraspecies *P. aeruginosa* competition assay between a strain lacking the *vgrG2b-PA0261* module and various isogenic attacker strains under H2-T6SS-conducive growth conditions at 25°C for 8 h. The competition assay between the parental strain (PAO1Δ*rsmA*) and itself, shown in gray, is the internal control for competitive parity. For (A) and (B), the strains used are described in the text. The values and error bars represent the mean ± SEM (n = 3 biological replicates). Statistical comparisons undertaken used one-way ANOVA with Dunnett's test using the parent versus prey competition as the comparator (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; ns, not significant).(B) Intraspecies competition assay showing that PA0261 is the immunity protein for VgrG2b~C-ter~. The prey strain produces PA0261 *in trans* with or without its native signal peptide (PA0261(no SP)) or harbors the empty vector. The attacker is the PAO1Δ*rsmA* parental strain. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.(C) Survival of *E. coli* expressing *vgrG2b*~C-ter~ or its catalytically inactive mutant *vgrG2b*~C-ter~ (E936A). The proteins are targeted to the periplasm by the Tat-dependent signal peptide of TorA in the pTat vector. Ten-fold serial dilutions of cultures (optical density 600 \[OD~600~\] 10^0^ to 10^−6^) were spotted on LB agar containing the noted concentrations of repressor (glucose) or inducer (IPTG for pET28a and arabinose for pTat) and grown for 24 h. Image is representative of three independent experiments.

To assess the role of PA0261 as the immunity protein neutralizing VgrG2b-mediated toxicity, we introduced the *PA0261* gene into the Δ*vgrG2bPA0261* strain *in trans*. Constitutive expression of *PA0261* in the prey strain abolishes the competitive growth advantage of the attacker, whereas the empty vector provides no such immunity ([Figure 4](#fig4){ref-type="fig"}B). Bioinformatic analysis of the PA0261 sequence revealed the presence of a putative N-terminal signal peptide, likely directing the protein into the periplasm ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Provision of *PA0261* without the sequence encoding this N-terminal portion (PA0261(no SP)) fails to prevent elimination by the parent ([Figure 4](#fig4){ref-type="fig"}B), suggesting that the predicted extracytoplasmic localization of this protein is needed to neutralize VgrG2b, similar to the immunity proteins of other *P. aeruginosa* periplasmic-acting toxins ([@bib45], [@bib87]).

If PA0261 requires its putative N-terminal signal peptide to act as an immunity protein, VgrG2b must elicit its toxicity beyond the cytoplasmic membrane. We ectopically produced VgrG2b~C-ter~ in *E. coli* and targeted the domain to the periplasm by fusing it to an N-terminal signal peptide from the Tat-dependent substrate TorA ([@bib76], [@bib94]). Production of VgrG2b~C-ter~ is not detrimental to *E. coli* when the protein remains in the cytoplasm, because this strain grows similarly to vector control strain ([Figure 4](#fig4){ref-type="fig"}C). However, this domain exhibits acute toxicity when targeted to the periplasmic compartment by the Tat-dependent signal peptide. Crucially, substitution of the putative catalytic glutamic acid residue to an alanine (E936A from HEXXH) renders VgrG2b~C-ter~ non-toxic in the periplasm, restoring growth. No differences in the levels of VgrG2b~C-ter~ production are observed between the periplasmic-targeted toxin and its inactive isoform ([Figure S2](#mmc1){ref-type="supplementary-material"}D), indicating that the putative enzymatic activity of the VgrG2b~C-ter~ metallopeptidase is responsible for toxicity. Mutation of the two histidine residues (H935A and H939A) coordinating the zinc ion in our structure also abolish periplasmic toxicity, supporting our designation of the HEXXH catalytic triad ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Interestingly, although raising the tonicity of media has been reported to rescue growth of bacteria producing the periplasmic-acting T6SS effectors Tse1 and Tse3, the addition of 0.5 M sucrose does not suppress the growth defect of *E. coli* producing VgrG2b~C-ter~ in the periplasm ([@bib87]) ([Figure S2](#mmc1){ref-type="supplementary-material"}F). This suggests that VgrG2b~C-ter~ may elicit an activity distinct from the D,L-endopeptidase and muramidase activities of Tse1 and Tse3, respectively (described later).

We sought to determine whether toxicity was displayed by orthologs of VgrG2b~C-ter~ and expressed the putative T6SS cargo effector ACIAD0053 from *A. baylyi* similarly. Surprisingly, induction of periplasmic-targeted ACIAD0053 expression does not hamper *E. coli* growth under identical conditions to that of intoxication by VgrG2b~C-ter~ ([Figure S2](#mmc1){ref-type="supplementary-material"}G). Nevertheless, reduction of the osmolarity of the medium (low-salt LB \[LB-LS\]) to increase bacterial susceptibility to lysis results in a drastic reduction in growth of the strain expressing pTat-*ACIAD0053*. Once more, alanine substitution of the residues of the catalytic triad (*ACIAD0053*^∗^) produces a non-toxic isoform ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H). These results indicate that members of the VgrG2b~C-ter~ metallopeptidase effector family act as potent periplasmic antibacterial toxins.

Functional Characterization of the PA0261 Immunity Protein Family {#sec2.5}
-----------------------------------------------------------------

To validate the toxin-immunity relationship of the VgrG2b~C-ter~-PA0261 pair, we investigated whether PA0261 could protect *E. coli* from VgrG2b~C-ter~-mediated toxicity. Coexpression of the immunity gene relieves the growth defect caused by the metallopeptidase ([Figure 5](#fig5){ref-type="fig"}A). As a specificity control, we expressed *tli4*, encoding the cognate immunity protein of the antibacterial H2-T6SS-dependent effector Tle4, which was unable to restore bacterial viability ([@bib45]). Immunoblot analysis determined that both immunity proteins are produced ([Figure S3](#mmc1){ref-type="supplementary-material"}A). This demonstrates that PA0261 is the cognate immunity determinant of the VgrG2b~C-ter~ toxin. Furthermore, the additional presence of a higher molecular weight band for PA0261-HA is indicative of the precursor form of a periplasmic protein, supporting the predicted localization of this immunity protein, which we later confirm ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S5A). We then used far-western dot blotting ([Figure 5](#fig5){ref-type="fig"}B) to investigate whether complex formation with the metallopeptidase domain was the neutralization mechanism of PA0261. We spotted recombinant VgrG2b~C-ter~ ([Figure S3](#mmc1){ref-type="supplementary-material"}B) or the C-terminal TTR domain of VgrG4b as bait proteins on nitrocellulose membrane and incubated them with a bacterial lysate overproducing hemagglutinin (HA)-tagged immunity proteins PA0261 or Tli3. Immunoblotting shows that despite production of both immunity proteins, only PA0261-HA binds to VgrG2b~C-ter~, and not to VgrG4b~C-ter~, suggesting a specific interaction with the metallopeptidase domain ([Figure 5](#fig5){ref-type="fig"}B). Furthermore, PA0261 binds the inactive metallopeptidase variant VgrG2b~C-ter~ (E936A), suggesting that the inactive variant is fully folded ([Figures 5](#fig5){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}C). This implies that PA0261 neutralizes VgrG2b~C-ter~ through complex formation, as has been shown for other biochemically characterized T6SS toxin-immunity pairs ([@bib87], [@bib96]).Figure 5PA0261 Is the Cognate Immunity Protein of VgrG2b~C-ter~(A) *PA0261* expression prevents intoxication of *E. coli* cells producing periplasmic VgrG2b~C-ter~. The non-cognate immunity protein Tli4 is used as a negative control. The values and error bars represent the mean ± SEM (n = 3 biological replicates). Statistical significance of the difference in survival compared with the strain under non-inducing conditions was calculated by one-way ANOVA followed by Tukey's multiple comparison test (^∗∗^p \< 0.01). See also [Figures S3](#mmc1){ref-type="supplementary-material"}.(B) PA0261 interacts with VgrG2b~C-ter~ in a far-western dot blot assay. Recombinant VgrG2b~C-ter~, its catalytic mutant, or VgrG4b~C-ter~ were spotted and incubated with *E. coli* cell lysates containing HA-tagged PA0261 or Tli3. Purified HA peptide is an anti-HA antibody binding control. The bottom panel shows an immunoblot of the lysate input samples confirming immunity protein production. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.(C and D) Disulfide bond formation is required for PA0261 to efficiently neutralize VgrG2b~C-ter~. *E. coli* strains produce PA0261-HA with the expression of pTat or pTat-*vgrG2b*~C-ter~ in the presence or absence of the *dsbA* gene and plated onto solid media. Measurement of colony size and images of the spots are shown in (C). A statistically significant difference between colony size of strains producing periplasmic-targeted VgrG2b~C-ter~ or not was determined by a two-tailed Student's t test (n = 4 biological replicates; ^∗∗∗^p \< 0.001). Immunoblotting determines production of VgrG2b~C-ter~ and the HA-tagged PA0261 proteins in (D), where lanes have been excised for clarity. The red arrow shows the position of the VgrG2b~C-ter~ band. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

In general, immunity proteins of T6SS toxins display little sequence identity with their orthologs, likely because of selective pressure solely on the conservation of toxin binding ([@bib88]). This phenomenon is also apparent in the PA0261 family; however, a multiple sequence alignment of homologous immunity proteins revealed the presence of cysteine residues in partially conserved positions ([Figure S4](#mmc1){ref-type="supplementary-material"}). Because PA0261 is a predicted periplasmic protein, the conservation of cysteine residues engenders the hypothesis that disulfide bond formation may be required for the function of the protein in the oxidizing environment of this compartment. To begin answering this question, we demonstrated through subcellular fractionation that PA0261 is found in the periplasm when expressed in *E. coli* ([Figure S5](#mmc1){ref-type="supplementary-material"}A). We assessed the ability of PA0261 to protect against the toxicity of periplasmic VgrG2b~C-ter~ in the absence of *dsbA*, encoding the major oxidoreductase of the disulfide bond formation (Dsb) system in *E. coli* ([Figure 5](#fig5){ref-type="fig"}C). The levels of PA0261 in the Δ*dsbA* mutant are greatly diminished, hampering the growth of this strain in the presence of VgrG2b~C-ter~ ([Figures 5](#fig5){ref-type="fig"}C and 5D). This indicates that the Dsb system contributes to the protection of bacterial cells from T6SS-mediated antagonism, in juxtaposition to a recent study demonstrating that a lack of DsbA in prey cells can indirectly confer protection against T6SS attack because of the improper folding of delivered toxins ([@bib62]). Crystal structures of immunity proteins such as those of the Tai4 family have also revealed the presence of disulfide bonds, extending the relevance of our observation to other families of T6SS immunity proteins ([@bib8], [@bib28], [@bib33]).

*In silico* examination of putative immunity proteins to members of the VgrG2b~C-ter~ family suggests that like PA0261, they are targeted to the cell envelope. However, the mechanisms of attaining this localization seem to be diverse. In *Enterobacteriaceae*, PA0261 homologs are predicted to be lipoproteins ([Figure S5](#mmc1){ref-type="supplementary-material"}B), whereas ACIAD0054, the putative immunity protein to ACIAD0053 in *A. baylyi*, appears to bear hallmarks of an N-terminal transmembrane helix ([Figure S4](#mmc1){ref-type="supplementary-material"}, top line). Irrespective of these differences, in both cases the bulk of the immunity protein would be exposed in the periplasm. The second residue following the lipobox cysteine residue of the predicted immunity lipoproteins in *Enterobacteriaceae* is often a glycine, likely directing the protein to the outer membrane rather than constituting an avoidance signal for the lipoprotein outer membrane localization (Lol) pathway as described by the +2 rule ([Figure S5](#mmc1){ref-type="supplementary-material"}B) ([@bib74], [@bib117]). Indeed, membrane fractionation of the *E. coli* cell envelope using selective detergent treatment showed that the PA0261 ortholog from *S. arizonae*, SARI_02726, is enriched in the outer membrane fraction ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Likewise, the *A. baylyi* ortholog ACIAD0054 was enriched in the inner membrane fraction as predicted ([Figure S5](#mmc1){ref-type="supplementary-material"}D). Determination of the localization of members of this immunity protein family supports the designation of VgrG2b~C-ter~-PA0261 as a periplasmic effector-immunity pair while highlighting the diversity of strategies employed by the immunity determinants to gain access to the periplasm, as summarized in [Figure S5](#mmc1){ref-type="supplementary-material"}E.

VgrG2b~C-ter~ Is Bacteriolytic but Does Not Display Peptidoglycan Hydrolase Activity {#sec2.6}
------------------------------------------------------------------------------------

Next, we investigated the activity of the VgrG2b~C-ter~ effector domain. To determine whether VgrG2b~C-ter~ induces growth arrest or lysis of target bacteria, we employed an outside-in approach, permeabilizing *E. coli* cells with a sublethal concentration of polymyxin B and measuring whether the toxin reduces culture turbidity. Although VgrG2b~C-ter~ (E936A) does not decrease the turbidity of the suspension, exogenous addition of lysozyme or VgrG2b~C-ter~ elicits suspension clarification, thereby showing that the metallopeptidase effector challenges cell integrity, having gained access to the periplasm ([Figure 6](#fig6){ref-type="fig"}A).Figure 6VgrG2b~C-ter~ Perturbs Cell Division(A) Incubation of recombinant VgrG2b~C-ter~ (red), VgrG2b~C-ter~ (E936A) (yellow) and lysozyme (blue) with polymyxin B-permeabilized *E. coli* cells. A decrease in turbidity indicates bacterial lysis. Points and error bars represent the mean ± SEM (n = 3 biological replicates). See also [Figure S6](#mmc1){ref-type="supplementary-material"}.(B) Single-cell analysis of *E. coli* cell morphology when expressing pTat, pTat-*vgrG2b*~C-ter~ or pTat-*vgrG2b*~C-ter~ (E936A). A series of representative fluorescence microscopy images of bacteria labeled with the membrane dye FM1-43 to highlight the cell exterior at different time points. Scale bar represents 2.5 μm. Image is representative of three independent experiments.(C) Localization of membrane blebs mediated by VgrG2b~C-ter~ activity. Using images from three independent time course experiments, typified by those in (B), the position of the membrane bleb of 230 intoxicated bacteria was plotted as its fraction of the cell length from midcell. The solid and dashed lines show the median and quartiles, respectively.(D) VgrG2b delivery by the H2-T6SS results in membrane blebbing. Fluorescent microscopy images show *P. aeruginosa* strains labeled with FM1-43 either alone (PAO1Δ*rsmA*, PAO1Δ*rsmA*Δ*tssE2*, or PAO1Δ*rsmA*Δ*vgrG2bPA0261*) or in competition (PAO1Δ*rsmA* or PAO1Δ*rsmA*Δ*tssE2* versus PAO1Δ*rsmA*Δ*vgrG2bPA0261*). Representative images from three independent experiments are shown. Scale bar represents 1 μm.(E) Localization of the site of membrane blebbing of PAO1Δ*rsmA*Δ*vgrG2bPA0261* in competition with the parental strain PAO1Δ*rsmA*, using the dataset represented in (D). Here, 147 intoxicated bacteria were analyzed identically to (C).

Because this bacteriolytic effector is a periplasmic-acting metallopeptidase, we reasoned that it might target either the peptide bonds in the cell wall or a protein within the cell envelope. We probed the action of the toxin toward the bacterial cell wall with various approaches. In a turbidimetric assay, recombinant proteins were incubated with lyophilized *Micrococcus lysodeikticus* as a substrate, but while lysozyme reduces turbidity, VgrG2b~C-ter~ does not ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Similarly, zymography demonstrated that lysozyme produces a zone of clearing in a stained gel impregnated with purified *E. coli* sacculi, yet no such peptidoglycan degradation was apparent for VgrG2b~C-ter~ ([Figure S6](#mmc1){ref-type="supplementary-material"}B). An analogous assay for crude protease activity was also used, with a similar negative outcome ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Finally, quantification of muropeptides released through sacculus hydrolysis using high-performance liquid chromatography (HPLC) revealed that treatment with VgrG2b~C-ter~ does not alter the composition of either tetrapeptide-rich or pentapeptide-rich *E. coli* cell wall preparations ([Figures S6](#mmc1){ref-type="supplementary-material"}D--S6F). Thus, we conclude that VgrG2b~C-ter~ does not exhibit peptidoglycan hydrolase activity.

VgrG2b Induces Lysis by Apparent Perturbation of Cell Division {#sec2.7}
--------------------------------------------------------------

Next, we turned to single-cell analysis of *E. coli* producing the periplasmic-targeted metallopeptidase or its inactive variant from the pTat vector. Bacterial morphology was highlighted by staining the membranes with the fluorescent dye FM1-43. Over the course of 2.5 h, no alterations in rod-like *E. coli* cell shape were observed in bacteria harboring the empty vector or pTat-*vgrG2b*~C-ter~ (E936A). However, production of the active periplasmic metallopeptidase causes aberrant cellular morphology characterized by membrane blebbing, leading to cell rounding and lysis ([Figure 6](#fig6){ref-type="fig"}B). Periplasmic VgrG2b~C-ter~ is still toxic in high-osmolarity conditions ([Figure S2](#mmc1){ref-type="supplementary-material"}F), suggesting that the effector does not cause lysis through global weakening of the cell wall as with Tse1 and Tse3 ([@bib87]). [Figure 6](#fig6){ref-type="fig"}C shows that blebbing predominately originates at midcell, leading to the cracking of the rod shape before rounding up, suggesting a defect in cell division similar to observations during β-lactam antibiotic administration ([@bib19], [@bib118]). This observation of site-dependent perturbation in cell shape is also in opposition to the notion of VgrG2b~C-ter~ exhibiting generic peptidoglycan hydrolase activity, unless the metallopeptidase requires a factor or structure specifically localized at the cell septum for its activation.

To discount the possibility that this phenotype is an artifact because of toxin overexpression, we monitored the morphology of *P. aeruginosa* cells subject to VgrG2b-mediated killing in competition assays. Upon attack of the susceptible Δ*vgrG2bPA0261* strain by its parent, we observed similar membrane blebbing, whereas no such morphological aberrations occurred when the attacker strain lacked a functional H2-T6SS (Δ*tssE2*) ([Figure 6](#fig6){ref-type="fig"}D). In addition, when the strains were incubated alone, no blebbing occurred. The blebs produced during elimination of VgrG2b-sensitive prey again localized to the septum, indicating that the mechanism of killing by the metallopeptidase domain is similar whether it is delivered by the T6SS or the effector is artificially targeted to the periplasm ([Figure 6](#fig6){ref-type="fig"}E). These results demonstrate that VgrG2b~C-ter~-induced blebbing is a physiologically relevant phenotype and that the target of this toxin is conserved between *E. coli* and *P. aeruginosa*.

Identification of Putative Interacting Partners of VgrG2b~C-ter~ {#sec2.8}
----------------------------------------------------------------

Because characterization of the biochemical activity of VgrG2b~C-ter~ had been unsuccessful, we turned to affinity purification-coupled mass spectrometry to investigate the identities of putative target proteins that interact with the toxin in the periplasm. A tagged inactive VgrG2b~C-ter~ variant was directed to the periplasm after which cellular proteins were crosslinked *in vivo* using dimethyl 3,3′-dithiobispropionimidate (DTBP). Affinity purification pulled down the tagged inactive metallopeptidase and any crosslinked interaction partners. Three independent replicates of the affinity-purified protein samples were subject to mass spectrometry analysis to identify candidate interactors of the metallopeptidase. This preliminary analysis found 89 proteins enriched in the tagged sample dataset compared with the untagged VgrG2b~C-ter~ control, which were present in at least two of the three replicates. Of these, just 19 proteins (21.3%) were found with MASCOT scores (representing the probability of true identification of the protein) higher than the threshold set to exclude background noise. Twelve of these 19 proteins (63.2%) are localized in the cell envelope and were subsequently considered candidate interactors of VgrG2b~C-ter~ ([Table S3](#mmc1){ref-type="supplementary-material"}). Three of the four highest-scoring candidates (MltC, PBP5, and PBP6a) are involved in peptidoglycan biogenesis. This suggests that the metallopeptidase may perturb the complex machinery, which maintains the cell wall, inhibiting cell division and producing the observed blebbing at midcell. If VgrG2b~C-ter~ acts through interference with peptidoglycan remodeling, it may be through direct cleavage of these identified target proteins; however, we cannot exclude that the interaction with periplasmic binding partners stimulates a putative peptidoglycan hydrolase activity of the toxin. The periplasmic action of VgrG2b~C-ter~ prevents growth of *E. coli* strains with single deletions in *mltC*, *dacA* (encoding PBP5), or *dacC* (encoding PBP6a), indicating that cleavage of one of these enzymes individually is not sufficient for toxicity ([Figure S7](#mmc1){ref-type="supplementary-material"}).

The dataset is also enriched with lipoproteins (8/12, or 67%), raising the possibility that VgrG2b~C-ter~ might interact with the linker region between the acylated cysteine residue of a lipoprotein and its main fold, resulting in disruption of its intrinsic localization. We monitored the abundance of two lipoproteins found in the dataset, MltC and LolB, in bacterial membranes after incubation of purified VgrG2b~C-ter~ or VgrG2b~C-ter~ (E936A) with bacterial lysates. The presence of VgrG2b~C-ter~ elicits a reduction in membrane-associated MltC or LolB in a manner dependent on its catalytic activity ([Figures 7](#fig7){ref-type="fig"}A and 7B). We examined the distribution of RcsF, an outer membrane lipoprotein that was identified below the significance cutoff in our pull-down experiments ([Table S3](#mmc1){ref-type="supplementary-material"}), and found that its levels were also diminished in the membrane fraction in the presence of the toxin ([Figure 7](#fig7){ref-type="fig"}C). The abundance of the periplasmic protein TEM-1 was unaltered in this assay ([Figure 7](#fig7){ref-type="fig"}D), suggesting that VgrG2b~C-ter~ may preferentially target lipoproteins; specifically, the toxin may cleave lipid anchors to release lipoproteins from membranes. Because this assay was conducted with non-physiological levels of both toxin and tagged lipoproteins, it is not possible to currently state whether MltC, LolB, or RcsF is a physiological target of VgrG2b when delivered by the T6SS. In all, our data indicate that the VgrG2b~C-ter~ metallopeptidase represents a hitherto-undescribed family of antibacterial T6SS effectors that appear to dysregulate the cell division process.Figure 7Incubation with VgrG2b~C-ter~ Reduces the Abundance of Lipoproteins in Bacterial Cell Membranes(A--C) Immunoblot analysis (left panels) and densitometry (right panels) of the abundance of lipoproteins MltC (A), LolB (B), and RcsF (C) in bacterial total membrane fraction (TMF) preparations in the presence of recombinant VgrG2b~C-ter~, VgrG2b~C-ter~ (E936A), or a buffer-only control.(D) Abundance of the periplasmic protein TEM-1 was assessed. The outer membrane protein PhoE acts as a marker of the total membrane fraction, and RpoB serves as the soluble fraction marker. A statistically significant difference in protein abundance between incubation with buffer or recombinant protein was determined by a two-tailed Student's t test (n = 3 biological replicates; ^∗^p \< 0.05, ^∗∗∗^p \< 0.001; ns, not significant). See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Previous work has proposed that VgrG2b is an anti-host effector that subverts the cytoskeleton ([@bib92]). VgrG2b interacts with members of the γTuRC, whereas VgrG2a, sharing 99.5% identity with VgrG2b across its spike and DUF2345 domains, does not, implying that the interaction occurs through the C-terminal extension of VgrG2b, encompassing the predicted metallopeptidase domain. The precise function of this domain was not explored, so it is unclear whether its catalytic activity is required for invasion. In addition, although ectopic expression of *vgrG2b* within host cells enhances *P. aeruginosa* uptake, it is possible that other bacterial factors are involved in the mechanism, because the internalization of neither inert particles nor other bacteria was shown. For example, other studies have found that *P. aeruginosa* can be internalized by non-phagocytic cells in a process that requires the H2-T6SS phospholipase effectors PldA and PldB ([@bib44]). Interestingly, PldA and PldB also display antibacterial activity, which necessitates a set of immunity proteins to avoid self-intoxication, and were coined trans-kingdom effectors ([@bib44], [@bib89]). In this study, we performed an in-depth characterization of VgrG2b and propose that it is also a trans-kingdom effector.

The identification of a small ORF downstream of genes encoding homologs of the VgrG2b~C-ter~ metallopeptidase family is a key finding in this work. We demonstrated the impact of the VgrG2b metallopeptidase domain on bacterial survival when reaching the periplasm of prey cells in an H2-T6SS-dependent manner. The HEXXH motif in its C-terminal domain had led to its designation as a putative zinc-dependent metallopeptidase, and here we present the crystal structure of this domain, which confirms this classification. Our phylogenetic analyses of VgrG2b~C-ter~-like proteins also find the corresponding gene within T6SS loci of diverse proteobacteria. It is frequently annotated as DUF4157, which corresponds to a small domain of approximately 80 residues encompassing the HEXXH motif. Our data show that mutations in the catalytic site abrogate the antibacterial activity, although we were unable to identify direct cleavage of a substrate by VgrG2b.

Our characterization of VgrG2b~C-ter~ as an antibacterial toxin is supported by the recent description of the ACIAD0053 protein from *A. baylyi* ([@bib85]). This study showed that an *A. baylyi* strain lacking *ACIAD0053-ACIAD0054* can be eliminated by its parent, leading to the designation of the locus as encoding a type VI metallopeptidase effector-immunity pair, Tpe1-Tpi1. We have additionally demonstrated that similar to VgrG2b~C-ter~, Tpe1 exerts its activity in the periplasm, whereas the cognate immunity protein Tpi1 resides in the inner membrane. The ortholog of this immunity determinant in *S. arizonae* is an outer membrane lipoprotein, but in both cases, the bulk of the immunity protein is exposed to the periplasm; accordingly, we also observe PA0261 of *P. aeruginosa* localizing to this compartment. It is therefore fitting to propose that the VgrG2b~C-ter~-PA0261 family of metallopeptidase effector-immunity pairs constitutes members of the Tpe-Tpi family.

In our study, we revealed the differing ability of VgrG2b~C-ter~ and the *A. baylyi* toxin Tpe1 to intoxicate *E. coli*. Work by Ringel and colleagues demonstrated Tpe1 toxicity in *A. baylyi* under standard laboratory conditions but failed to see an impact on *E. coli* ([@bib85]). We corroborate this observation under standard laboratory conditions but find that a defect in *E. coli* growth is elicited by Tpe1 in conditions of low salinity, implying that osmolarity, or salt per se, may regulate its action. Recently, a study of effector synergy within a delivered payload indicates that conditional efficacy is a common phenomenon among T6SS toxins; thus, toxin efficiency should be considered in the context of the whole T6SS-delivered payload ([@bib55], [@bib99]). It may be that the biochemical action of Tpe1 is inhibited by moderate salinity, or rather its target is regulated by this condition. Alternatively, this experimental setup may simply reflect a more environmentally relevant condition and imply that VgrG2b~C-ter~ is a more robust enzyme. Salinity is known to regulate periplasmic proteins such as peptidoglycan biosynthetic enzymes, presenting the possibility that these toxins may interact with different members of a family of peptidoglycan remodeling enzymes such as penicillin-binding proteins (PBPs) or lytic transglycosylases (LTases) ([@bib69], [@bib77]). Indeed, *P. aeruginosa*, *A. baylyi*, and *E. coli* possess differing quotas of these peptidoglycan hydrolases, rendering species-dependent nuances in substrate targeting an attractive hypothesis ([@bib24], [@bib79]).

We observed bulge formation at sites of septation resulting from the activity of VgrG2b~C-ter~. Recently, a T6SS effector inhibiting bacterial cell division was described in *Serratia proteamaculans*, for which ADP ribosylation of the essential cell division protein FtsZ prevents Z-ring formation, causing bacterial elongation because of inhibition of septation ([@bib104]). The cell division defect mediated by VgrG2b~C-ter~ that we observe appears to be distinct, characterized by midcell blebbing. This is reminiscent of the inhibition of the cell wall biosynthesis machineries by β-lactam antibiotics, in which the balance of peptidoglycan growth and degradation is disrupted, causing severe morphological aberrations and cell lysis ([@bib18], [@bib25], [@bib103]). Class A PBPs possess transpeptidase (TPase) and glycosyltransferase activities to incorporate new monomers into the sacculus, and these biosynthetic processes are coordinated with the degradative action of enzymes such as LTases, amidases, and carboxypeptidases (CPases), which modify the peptidoglycan to regulate its growth and permit septation of daughter cells ([@bib26]). These enzymes form large complexes, whose subcellular localization often regulates their activities, and dysregulation of this process usually results in lysis. For example, the recruitment to midcell and subsequent activity of the TPase LdtD requires the concerted actions of PBP5, PBP6a, and PBP1b to facilitate septation under certain stress conditions, the latter of which is also associated with LTases MltA and MltG and is recruited to the septum by the lipoprotein LpoB ([@bib43], [@bib70], [@bib71], [@bib78], [@bib106], [@bib111], [@bib119]). Similarly, perturbation of the localization of EnvC and NlpD to the division site, which controls the activity of amidases required for separation of daughter cells, results in septation failure ([@bib105], [@bib107], [@bib108]).

Consequently, it is thought that functional redundancy may help to insulate this crucial process from environmental insults, and correspondingly, individual deletions in LTases and many PBP genes often do not produce phenotypic changes, because the enzymes display partially overlapping functions for robust control of cell division in changing conditions ([@bib22], [@bib38], [@bib79], [@bib80]). Our pull-down assays identified the membrane-associated LTase MltC and the D,D-CPases PBP5 and PBP6a as possible interaction partners of VgrG2b~C-ter~, yet individually they are dispensable for effector-mediated toxicity, potentially as a consequence of built-in redundancy. The precise biochemical activities and functions of these peptidoglycan biosynthetic enzymes have only started to be unraveled ([@bib3], [@bib23], [@bib67], [@bib80]), so further work is required to establish their relevance during intoxication by the T6SS.

We found that VgrG2b~C-ter~ depletes several lipoproteins from membranes, implying broad target specificity by associating with the lipidated linker region of these proteins. We speculate that the activity VgrG2b~C-ter~ may disrupt the localization of lipoproteins associated with cell envelope maintenance such as membrane-associated LTases, the cell wall anchoring protein Lpp, or components of the Lol and Bam machineries, thereby perturbing bacterial cell division. Targeting of lipidated substrates has been described for bacterial effectors of the type III secretion system, namely, YopT of *Yersinia enterocolitica* and IpaJ of *Shigella flexneri*. These proteases are delivered into host cells, where they cleave the isoprenyl and *N*-myristoyl anchors of small guanosine triphosphatases (GTPases), respectively, to disrupt host cell signaling and facilitate bacterial survival ([@bib12], [@bib97]). Indeed, these effectors target specific families of GTPases during infection, rather than a single protein; thus, the notion of target promiscuity for VgrG2b~C-ter~ has an intriguing precedent ([@bib13], [@bib32]).

In summary, we find that besides its described role in invasion of eukaryotic cells, the evolved VgrG2b spike protein of *P. aeruginosa* has a direct role in bacterial antagonism. Given the vast dissimilarity between host microtubule manipulation and bacteriolytic activity, reconciliation of VgrG2b metallopeptidase dual role warrants further work to shed light on the activity of this effector within eukaryotic systems. In prokaryotes, the C-terminal metallopeptidase domain elicits acute toxicity when targeted to the periplasmic space, resulting in dysregulation of bacterial morphology and cell lysis. The prevalence of this family of T6SS effector proteins suggests conservation of its target, so elucidation of its antibacterial mechanism may help progress both our knowledge of bacterial cell division and how to target this process with therapeutic compounds.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse monoclonal anti-RpoBBiolegendCat\#663006; RRID: [AB_2565555](nif-antibody:AB_2565555){#interref65}Rabbit polyclonal anti-Hcp2[@bib47]N/ARabbit polyclonal anti-VgrG2b[@bib92]N/ARabbit polyclonal anti-LasBGift from Romé VoulhouxN/ARabbit polyclonal anti-VgrG4b[@bib2]N/AMouse monoclonal anti-MycMilliporeCat\#05-724; RRID: [AB_309938](nif-antibody:AB_309938){#interref70}Mouse monoclonal anti-HABiolegendCat\#MMS-101P; RRID: [AB_2314672](nif-antibody:AB_2314672){#interref75}Mouse monoclonal anti-TEM-1QED BioscienceCat\#15720; RRID: [AB_129940](nif-antibody:AB_129940){#interref80}Mouse monoclonal anti-HisSigmaCat\#H1029; RRID: [AB_260015](nif-antibody:AB_260015){#interref85}Rabbit polyclonal anti-DsbAGift from Despoina MavridouN/ARabbit polyclonal anti-SecAGift from Jan TommassenN/ARabbit polyclonal anti-PhoEGift from Jan TommassenN/A**Bacterial and Virus Strains***Pseudomonas aeruginosa* PAO1Dieter Haas Laboratory (Filloux lab wild type)N/A*P. aeruginosa* PAO1Δ*rsmA*This paperN/A*P. aeruginosa* PAO1Δ*rsmA*Δ*tssE2*[@bib114]N/A*P. aeruginosa* PAO1Δ*rsmA*Δ*vgrG2b*[@bib116]N/A*P. aeruginosa* PAO1Δ*rsmA*Δ*vgrG2bPA0261*This paperN/A*P. aeruginosa* PA14[@bib56] (Whitney lab wild type)N/A*P. aeruginosa* PA14Δ*rsmA*Δ*amrZ*This paperN/A*P. aeruginosa* PA14Δ*rsmA*Δ*amrZ* Δ*PA14_03210* (*PA0261*^PA14^)This paperN/A*P. aeruginosa* PA14Δ*rsmA*Δ*amrZ*Δ*PA14_03210-20* (*vgrG2bPA0261*^PA14^)This paperN/A*P. aeruginosa* PA14Δ*rsmA*Δ*amrZ*Δ*clpV2*Δ*PA14_03210*This paperN/A*Escherichia coli* DH5αLab StockN/A*E. coli* BL21 (λDE3)Lab StockN/A*E. coli* B834 (λDE3)Lab StockN/A*E. coli* CC118λ*pir*[@bib39]N/A*E. coli* Sm10λ*pir*[@bib68]N/A*E. coli* 1047 pRK2013[@bib36]N/A*E. coli* XL1-BlueAgilentCat\#200249*E. coli* MC4100[@bib15]N/A*E. coli* MC1061[@bib16]N/A*E. coli* CS703/1[@bib66]N/A*E. coli* MC1000[@bib63]N/A*E. coli* MC1000 *dsbA::Km*[@bib63]N/A*E. coli* BW25113Keio collectionN/A*E. coli* BW25113Δ*mltC*Keio collectionN/A*E. coli* BW25113Δ*dacA*Keio collectionN/A*E. coli* BW25113Δ*dacC*Keio collectionN/A*Acinetobacter baylyi* ADP1Suzana SalcedoN/A**Chemicals, Peptides, and Recombinant Proteins**ArabinoseSigma AldrichCat\#A3256Cellosyl(Gift from Hoechst, Germany)N/AFM1-43ThermoFisherCat\#T3163HA PeptideSigma AldrichCat\#11666975001IPTGMelfordCat\#MB1008LysozymeRocheCat\#10837059001Proteinase KQIAGENCat\#19131Thrombin ProteaseSigma AldrichCat\#GE27-0846-01VgrG4b~C-ter~[@bib2]N/AX-galMelfordCat\#M1001**Critical Commercial Assays**SuperSignal West Pico PLUS Chemiluminescent SubstrateThermoFisherCat\#34580**Deposited Data**VgrG2b~C-ter~ crystal structureThis paperPDB: [6H56](pdb:6H56){#intref0010}VgrG2b~C-ter~ crystal diffraction dataThis paperZenodo: 10.5281/zenodo.3246345**Oligonucleotides**See [Table S4](#mmc2){ref-type="supplementary-material"} for full list of primersN/A**Recombinant DNA**pBBR1-MCS-4[@bib52]N/ApBBR1-MCS-4-*tssE2-his*~*6*~This paperN/ApET28aNovagenCat\#69864pET28a-*vgrG2b*~C-ter~This paperN/ApET28a-*vgrG2b*~C-ter~ (E936A)This paperN/ApET28a-*mltC*This paperN/ApET28a-*lolB*This paperN/ApET28a-*rcsF*This paperN/ApTatThis paperN/ApTat-*vgrG2b*~C-ter~*-myc*This paperN/ApTat-*vgrG2b*~C-ter~ (E936A)*-myc*This paperN/ApET22bNovagenCat\#69744pET22b-*PA0261-HA*This paperN/ApET22b-*tli4-HA*This paperN/ApBBR1-MCS-5[@bib52]N/ApBBR1-MCS-5-*PA0261-HA*This paperN/ApBBR1-MCS-5-*PA0261*(no SP)*-HA*This paperN/ApBBR1-MCS-5-*tli3-HA*[@bib116]N/ApTat-*ACIAD0053-FLAG*This paperN/ApTat-*ACIAD0053^∗^-FLAG*This paperN/ApET22b-*SARI_02726-HA*This paperN/ApET22b-*ACIAD0054-HA*This paperN/ApET22b-*vgrG2a*~C-ter~*-strepII*This paperN/ApET22b-*vgrG2b*~C-ter~ (E936A)This paperN/ApET22b-*vgrG2b*~C-ter~ (E936A)*-strepII*This paperN/ApSCrhaB2-CV[@bib14]N/ApSCrhaB2-CV-peri-*vgrG2b*(847-1019)^PA14^This paperN/ApSCrhaB2-CV-peri-*vgrG2b*(847-1019) ^PA14^ (H935A)This paperN/ApSCrhaB2-CV-peri-*vgrG2b*(847-1019) ^PA14^ (E936A)This paperN/ApSCrhaB2-CV-peri-*vgrG2b*(847-1019) ^PA14^ (H939A)This paperN/ApPSV39-CV[@bib102]N/ApPSV39-CV-*PA14_03210* (*PA0261*^PA14^)This paperN/AMini-CTX-*lacZ*[@bib7]N/ApEXG2[@bib84]N/ApEXG2-Δ*PA14_52570* (*rsmA*^PA14^)This paperN/ApEXG2-Δ*PA14_20290* (*amrZ*^PA14^)This paperN/ApEXG2-Δ*PA14_03210* (*PA0261*^PA14^)This paperN/ApEXG2-Δ*PA14_03210-20* (*vgrG2bPA0261*^PA14^)This paperN/ApEXG2-Δ*PA14_42980* (*clpV2*^PA14^)This paperN/ApKNG101[@bib49]N/ApKNG101-Δ*rsmA*[@bib2]N/ApKNG101-Δ*tssE2*[@bib114]N/ApKNG101-Δ*vgrG2b*[@bib116]N/ApKNG101-Δ*vgrG2bPA0261*This paperN/A**Software and Algorithms**Prism 8.0Graphpad<https://www.graphpad.com/scientific-software/prism/>FIJI[@bib95]<https://fiji.sc/>PyMolSchrödinger<https://pymol.org/2/>COOT[@bib27]<https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Alain Filloux (<a.filloux@imperial.ac.uk>). All reagents generated in this work shall be shared upon request without restrictions.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

Bacterial strains were grown at 37°C in lysogeny broth (LB) with agitation unless stated otherwise. All cultures were supplemented with antibiotics and other supplements where necessary. The following antibiotic concentrations were employed for *E. coli*: 50 μg/ml kanamycin, 50 μg/ml ampicillin, 50 μg/ml streptomycin, 34 μg/ml chloramphenicol, 15 μg/ml tetracycline, 200 μg/ml trimethoprim and 15 μg/ml gentamicin. For *P. aeruginosa*, 50 μg/ml gentamicin, 2 mg/ml streptomycin, 50 μg/ml tetracycline and 100 μg/ml carbenicillin were used. Deletion mutants were constructed as previously described ([@bib109]). Briefly, splicing by overlap extension polymerase chain reaction (PCR) was used to generate DNA fragments of regions of the *P. aeruginosa* genome with in-frame gene deletions introduced, which were cloned into the suicide vector pKNG101. After mobilisation into *P. aeruginosa* by three-partner conjugation from *E. coli* CC118λpir and with the 1047 pRK2013 helper strain, selection of conjugants was achieved on Vogel-Bonner medium (20 mM magnesium sulfate heptahydrate, 200 mg anhydrous citric acid, 1 g potassium phosphate dibasic and 350 mg ammonium sodium phosphate dibasic tetrahydrate) supplemented with 1.5% (w/v) agar and 2 mg/ml streptomycin. Counter-selection on solid LB medium containing 20% (w/v) sucrose at ambient temperature for 72 h lead to plasmid excision and generation double recombinants. All mutants were confirmed by PCR and sequencing.

Method Details {#sec4.4}
--------------

### Secretion assays and immunoblot analysis {#sec4.4.1}

*P. aeruginosa* secretion assays were conducted as previously described ([@bib2]) with the following modifications. Cultures were inoculated into 25 mL tryptic soy broth (TSB) at OD~600~ 0.1 and grown for 8 h at 25°C with agitation. Supernatants were cleared of cells by four rounds of centrifugation at 4000 *g* at 4°C, successively taking the uppermost supernatant. Proteins were precipitated with 10% trichloroacetic acid supplemented with 0.03% sodium deoxycholate overnight at 4°C. Separation of protein samples by SDS-PAGE and subsequent immunoblot analysis was conducted as previously described ([@bib35]) with the exception of culture supernatants being loaded at 20x concentrated in comparison to the whole cell extracts.

Here, bacterial culture samples were normalized to an OD~600~ 1.0. Gels containing 6%, 8%, 10%, 12% or 15% polyacrylamide were used to separate protein samples by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in Tris-glycine-SDS buffer (0.3% (w/v) Tris, 1.44% (w/v) glycine, 0.01% (w/v) SDS) at 180 V, depending on the size resolution desired. Gels were prepared using Mini-PROTEAN Tetra handcast systems (BioRad) and the Precision Plus Protein Kaleidoscope Prestained Protein Standards marker (Bio-Rad) was loaded to show the migration of molecular weight standards. Samples were stained with Coomassie Brilliant Blue R250 (Sigma) or subjected to immunoblotting. For immunoblot analysis, protein samples were transferred to 0.2 μm nitrocellulose membrane (Amersham Biosciences) after incubation in transfer buffer (10% (v/v) Tris-glycine-SDS buffer, 20% (v/v) ethanol) using a TransBlot SD semi-dry transfer cell (BioRad) at 24 V and 0.18 A for 44 min. Membranes were blocked using a solution of 5% (w/v) skimmed milk powder (Sigma), 50 mM Tris-HCl pH 8.0, 150 mM NaCl and 0.1% (v/v) Tween-20 for 1 h before the addition of primary antibodies. Primary antibodies were used at 1/1000 dilutions in blocking buffer overnight at 4°C, aside from anti-RpoB and anti-PhoE, which were used at 1/5000 and 1/2000, respectively. Membranes were washed in blocking buffer lacking milk three times before the addition of horseradish peroxidase-conjugated secondary antibodies for 45 min at room temperature. Secondary antibodies were used at 1/5000 dilution. Membranes were once again washed three times before development using SuperSignal West Pico Chemiluminescent substrate (ThermoFisher) and imaging using a LAS-3000 imager (Fujifilm).

### Protein purification {#sec4.4.2}

Purification of proteins was performed as described previously ([@bib2]). Briefly, *E. coli* BL21 (λDE3) pET28a-*vgrG2b*~C-ter~ or pET28a-*vgrG2b*~C-ter~ (E936A) were grown in terrific broth at 37°C for 2 h prior to induction of gene expression by addition of 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and growth overnight at 18°C. B834 (λDE3) was the host for selenomethionine incorporation. Cell harvesting and protein purification was done as described, but without protease inhibitors. The C-terminal hexahistidine tag was cleaved by thrombin protease (Sigma Aldrich) and dialysed into low imidazole buffer (50 mM Tris-HCl pH 8.0, 500 mM sodium chloride, 20 mM imidazole) before separation from non-cleaved protein on a Ni^2+^-NTA column in the flow-through fractions. Proteins were concentrated in Amicon Ultra Centrifugal Filter Units (Millipore) before further purification by SEC using a Superdex S200 10/300 GL column (GE Healthcare). Purity of elution fractions was determined by Coomassie staining of proteins separated by SDS-PAGE.

### Crystallization experiments and structure determination {#sec4.4.3}

Purified VgrG2b~C-ter~ was concentrated to 12 mg/ml and centrifuged for 20 minutes at 4°C to remove dust and aggregates. The protein was crystallized by vapor diffusion at 20°C, with small crystals growing in 100 Mm bis-tris pH 6.5 and 45% polypropylene glycol P400. Their space group was *P*3~1~ and they diffracted to 3.2 Å. The structure was solved by experimental phasing, whereby crystals of selenomethionylated protein were grown in 100 mM sodium citrate pH 4.7, 20 mM magnesium chloride, 50 mM sodium chloride and 29% PEG400. These crystals had space group *P*42~1~2 and diffracted to 3.0 Å. Data were collected at the beamlines i02 and i04 of Diamond Light Source (Didcot, UK) from crystals flash-frozen in liquid nitrogen without additional cryoprotection. Diffraction data from both experiments can be downloaded from Zenodo ([https://doi.org/10.5281/zenodo.3246345](10.5281/zenodo.3246345){#intref0040}). Data were processed in XDS ([@bib48]). The structure was solved by single anomalous dispersion based on the selenomethionine signal, although due to limited resolution and low anomalous signal, four datasets were combined in Blend ([@bib31]) to determine the anomalous substructure in SHELX ([@bib98]). A partial model comprising secondary structure elements was built by phenix.autobuild over several rounds of rebuilding and refinement before being used for molecular replacement with the *P*3~1~ dataset in Phaser ([@bib65]). The new model was rebuilt in Coot and refined in Refmac5 ([@bib73]), phenix.refine ([@bib1]) and Buster-TNT ([@bib9]) until convergence. The crystallographic statistics are summarized in [Table S1](#mmc1){ref-type="supplementary-material"}. Interface analysis was performed on the Proteins, Interfaces, Structures and Assemblies (PISA) server while molecular graphics figures were prepared with PyMol (Schrödinger).

### Differential scanning fluorimetry {#sec4.4.4}

Analysis of the thermal stability of recombinant VgrG2b~C-ter~ protein in the presence and absence of zinc ions was determined using a Mx3005P qPCR instrument (Agilent). VgrG2b~C-ter~ was used at 1.25 μM, in a buffer of 10 mM HEPES pH 7.4 and 100 mM NaCl supplemented with zinc acetate as indicated. The fluorescent dye SyproOrange (Sigma Aldrich) was used at a 1/1000 dilution and the thermal unfolding of VgrG2b~C-ter~ was monitored between 25-98°C at a rate of 1.5K/min. Excitation occurred at 492 nm and emission fluorescence at 610 nm was measured every 40 s. Non-linear least-squares fitting ([@bib51]) was used to analyze the raw data and the melting point of each sample was determined from the inflection point of the fitted curve.

### SEC-MALLS {#sec4.4.5}

The oligomeric state of recombinant VgrG2b~C-ter~ was determined using SEC-MALLS and refractometry. VgrG2b~C-ter~ was loaded onto a Superdex 75 10/30 column (GE Healthcare) and separated at 20°C with a flow rate of 0.5 ml/min. MALLS detection was performed with a miniDAWN TREOS detector (Wyatt Technology) using a laser emitting at 657.3 nm. The refractive index of the solution was measured with an Optilab T-rEX detector (Wyatt Technology) with the refractive-index increment (dn/dc) set to 0.185 ml/g. Weight-averaged molar masses were calculated using ASTRA software (Wyatt Technology).

### Bacterial competition assays {#sec4.4.6}

The *P. aeruginosa* strains used in intraspecies competitions were differentiated by integration of Mini-CTX-*lacZ* at the chromosomal *att* site of the prey strains, permitting blue/white screening on 5-bromo-4-chloro-3-indolyl-D-galactopyranoside (X-gal)-containing solid media. Bacteria were grown overnight in 5 mL LB with appropriate antibiotics before normalization to an OD~600~ 3.0 in 1 mL sterile PBS. Attacker and prey strains were mixed at a 1:1 ratio and 5 μl competition drops were spotted onto dry 3% low salt LB agar (10 g bactopeptone, 5 g yeast extract, 30 g bacteriological agar per liter). After drying, competitions were incubated at 25°C for 24 h. Both the input and output of competition spots were serially diluted in PBS and plated on LB containing 100 μg/ml X-gal for enumeration of colony forming units (CFU). The competitive index was calculated as the ratio between the input and output attacker/prey ratios. For self-intoxication assays on solid media, overnight cultures of *P. aeruginosa* strains were normalized and spotted onto nitrocellulose membrane on 3% LB agar containing gentamicin and 300 μM IPTG. CFUs were enumerated after 18 hours of growth at 25°C. For the corresponding growth curves in liquid media, overnight cultures were back-diluted 200-fold into LB broth containing gentamicin and 300 μM IPTG. Cultures were grown at 25°C with agitation in a 96-well plate, and OD~600~ readings were taken every 30 minutes for 18 hours using a Synergy 4 Microplate Reader (Biotek Instruments).

### Bacterial intoxication assays {#sec4.4.7}

*E. coli* DH5α was transformed with pTat plasmids harboring variants of T6SS metallopeptidase genes to target the gene products to the periplasmic space and BL21 (λDE3) was the host when pET28a and pET22b plasmids were used. Investigation into the role of cell wall biosynthetic enzymes employed the corresponding deletion strains and the BW25113 parent strain from the Keio collection as hosts ([@bib5]). The host for the peri-*vgrG2b*(847-1019) plasmids was *E. coli* XL1-Blue harboring the immunity gene under a leaky promoter, since the presence of the plasmid containing the wild-type peri-*vgrG2b*(847-1019) construct was otherwise not tolerated. Overnight cultures of the strains harboring the vectors of interest were grown in LB, normalized and serially diluted. Dilutions were spotted on LB agar containing inducer (100 μM IPTG, 0.2% arabinose or 0.3% rhamnose) or repressor (0.2% glucose). To modify the osmolality of solid media, low tonicity was achieved with low salt LB agar, while to raise it LB agar was supplemented with 500 mM sucrose.

### Subcellular fractionation of bacterial cells {#sec4.4.8}

The localization of proteins within bacterial cells was probed by membrane fractionation and periplasmic extraction procedures. To extract the periplasm, *E. coli* cells producing the proteins of interest were normalized to OD~600~ 20 and resuspended in 200 μl spheroplast buffer (200 mM Tris-HCl pH 8.0, 500 μM EDTA, 500 mM sucrose) to which 50 μg hen egg-white lysozyme (Roche) was added and incubated at 4°C for 15 min. To this, 720 μl half-strength spheroplast buffer was added and incubated for a further 15 min to release the periplasmic contents. Centrifugation at 5000 *g* at 4°C for 5 min separated the spheroplasts from the periplasmic fraction. To assess the presence of proteins in the inner and outer membranes, *E. coli* cultures were resuspended in sonication buffer (50 mM Tris-HCl pH 8.0, 1 mM EDTA) and lysed using a Vibra-Cell sonicator (Sonics & Materials, Inc.) on ice. Centrifugation at 4000 *g* cleared the soluble fraction from the cellular debris before ultracentrifugation at 100 000 *g* for 1 h at 4°C pelleted the total membrane fraction. After washing the membranes with sonication buffer, solubilisation buffer (15 mM Tris-HCl pH 7.4, 2% sodium lauroyl sarcosinate) was added to differentially solubilise the inner and outer membrane proteins before further ultracentrifugation to pellet the insoluble outer membrane protein fraction. The membrane fractions were separated, and the pellet was washed with solubilisation buffer. All fractions were normalized prior to analysis by SDS-PAGE.

### Far-western dot blot analysis {#sec4.4.9}

Protein-protein interactions were probed by far-western dot blotting as described previously ([@bib64]). Briefly, 10 μg purified protein of interest or HA peptide (Sigma Aldrich) was spotted onto nitrocellulose membrane and air-dried before blocking. Lysates of *E. coli* strains producing the prey proteins with C-terminal HA tags were obtained by sonication and normalized to OD~600~ 10 in protein binding buffer (20 mM Tris-HCl pH 7.6, 100 mM sodium chloride, 10% glycerol, 0.1% Tween-20, 2% skimmed milk powder). Membranes were incubated with the lysates or protein binding buffer overnight at 4°C prior to washing three times and immunoblotting for the bait and prey proteins.

### Turbidometric and colorimetric analysis of VgrG2b activity {#sec4.4.10}

Generic protease activity of 10 μg recombinant VgrG2b~C-ter~, its inactive mutant and a proteinase K control was assessed using 1% proteinaceous substrates bovine serum albumin and gelatin in 2% bacteriological agar plates. After incubation at 37°C for 24 h, plates were stained with amido black solution ([@bib110]) to visualize zones of proteolysis. Lysozyme activity of recombinant proteins utilized the lyophilised substrate *Micrococcus lysodeikticus* (Sigma Aldrich) as previously documented ([@bib60]). The polymyxin B-mediated permeabilisation of the bacterial outer membrane to permit access of exogenous proteins to the periplasmic space was performed as described elsewhere ([@bib10]), except *E. coli* was employed. *E. coli* DH5α was resuspended in turbidometry buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl) at OD~600~ 0.2 and incubated with 4 μg/ml polymyxin B. After addition of 10 μg purified protein, the turbidity at OD~600~ was monitored at five-minute intervals for 1 h.

### Zymography {#sec4.4.11}

Peptidoglycan was purified from 500 mL *E. coli* MC4100 culture for zymographic analysis as described elsewhere ([@bib10], [@bib93]). Briefly, 10 μg purified protein was separated by SDS-PAGE in gels impregnated with 0.1% peptidoglycan before the gel was washed with ddH~2~O and equilibrated in renaturation buffer (10 mM Tris-HCl pH 7.5, 10 μM zinc acetate, 0.1% Triton X-100). Renaturation of the proteins occurred overnight at 37°C and after washing the peptidoglycan was stained with methylene blue (0.1% methylene blue, 0.01% potassium hydroxide) to visualize zones of clearing corresponding to peptidoglycan hydrolase activity.

### Peptidoglycan hydrolase assay {#sec4.4.12}

Peptidoglycan was isolated from *E. coli* MC1061 ([@bib16]) and CS703/1 ([@bib66]) strains as described previously ([@bib34]). Briefly, *E. coli* cultures were grown to mid-exponential phase before centrifugation to pellet the cells. Cell membranes were solubilised by adding the cells in ice-cold water drop-wise into a boiling 8% (w/v) SDS solution under agitation. After cooling overnight, cell sacculi were collected by centrifugation at 130 000 *g* for 1 h at room temperature and washed four times to remove residual SDS. Glycogen and covalently-linked proteins were released by treatment with amylase and pronase, respectively, before boiling in SDS once more. Purified peptidoglycan was washed four more times in distilled water before resuspension in 20 mM sodium phosphate buffer pH 4.8. Reactions were carried out in 50 mM Tris-HCl pH 7.5 containing 150 mM NaCl, 0.05% Triton X-100 and 1 mM ZnCl~2~. Purified VgrG2b~C-ter~ or VgrG2b~C-ter~ (E936A) (5 μM) was incubated with 0.1 mg/ml purified peptidoglycan in a final volume of 100 μl for 4 h at 37°C in a thermoshaker at 850 rpm. Reactions were terminated by boiling the samples at 100°C for 10 min. Next, 20 μl of 20 mM sodium phosphate pH 4.8 and 1 μM cellosyl muramidase (kindly provided by Hoechst, Germany) were added and incubated over night at 37°C. Samples were centrifuged at 13 000 rpm for 10 min and the supernatant containing the soluble muropeptides was collected. Samples were reduced using sodium borohydride and adjusted to pH 4-5 before reduced muropeptides were separated by reversed-phase HPLC ([@bib34]).

### Microscopy techniques {#sec4.4.13}

*E. coli* DH5α harboring pTat plasmids were grown to OD~600~ 0.5, resuspended in LB containing chloramphenicol, 0.2% arabinose and 5 μg/ml FM1-43 lipophilic dye, and 1 μl was spotted onto a coverslip under an agarose pad for microscopic analysis. Growth of bacteria was monitored every 30 min in a heated chamber at 37°C using an Axio Observer Z1 epifluorescent microscope (Zeiss). Image processing and cell length measurements were performed with FIJI software. Analysis of *P. aeruginosa* cell morphology was conducted similarly; however, competitions were initialised as described in the section "Bacterial competition assays." To investigate the role of DsbA in PA0261-mediated neutralisation of periplasmic VgrG2b~C-ter~, *E. coli* MC1000 or its *dsbA* mutant derivative harboring the relevant plasmids were normalized to OD~600~ 1 after overnight growth. Serial dilution followed and spots were plated on LB agar containing the appropriate antibiotics in inducing or repressing conditions. Images of the spots were acquired with a Leica M205FA stereomicroscope with a 1x objective and colony area measurements were also determined within FIJI software.

### Mass spectrometry analysis {#sec4.4.14}

Mass spectrometry analysis was conducted by the Plateforme Protéomique Structurale et Fonctionelle at the Institut Jacques Monod, Paris. Briefly, samples underwent on-bead digestion with 12.5 μg/ml sequencing-grade trypsin (Promega), before peptide analysis on an Orbitrap Fusion Tribrid mass spectrometer coupled to an Easy-spray nanoelectrospray ion source and an Easy nano-LC Proxeon 1000 liquid chromatography system (all Thermo Scientific). Chromatographic separation of the peptides was achieved by an Acclaim PepMap 100 C18 pre-column and a PepMap-RSLC Proxeon C18 column at a flow rate of 300 nl/min. The solvent gradient consisted of 95% solvent A (water, 0.1% (v/v) formic acid) to 35% solvent B (100% acetonitrile, 0.1% (v/v) formic acid) over 98 minutes. An Orbitrap mass spectrometer analyzed the peptides in full ion scan mode, with the resolution set at 120 000 with a *m/z* mass range of 350 - 1550. High energy collision-induced dissociation activation with a collisional energy of 28% permitted fragment acquisition with the quadruple isolation width of 1.6 Da. The linear ion trap was employed in top-speed mode to acquire the MS/MS data with a 50 s dynamic exclusion and a 1 min repeat duration. Maximum ion accumulation times were set to 250 ms for MS acquisition and 60 ms for MS/MS acquisition in parallelisation mode. A MASCOT search server (Matrix Science, version 2.5.1) was used in-house to identify the peptides. Here, a mass tolerance of 7 ppm was set for precursor ions and 0.5 Da for fragments. Identified modifications included acetylation (N-terminal), oxidation (Met) and phosphorylation (Ser, Thr or Tyr), and two missed trypsin cleavage sites were permitted. The *E. coli* SwissProt database (August 2017) was searched using the MS/MS data, while searching the *P. aeruginosa* database confirmed the presence of the bait proteins. A false-discovery rate of 1% was determined with the percolator algorithm, below which the identities of peptides could be assigned.

### Analysis of lipoprotein abundance {#sec4.4.15}

Overnight cultures of *E. coli* BL21 (λDE3) harboring pET28a-*mltC*, -*lolB*, *rcsF* or pET22b were back-diluted in LB containing the appropriate antibiotics and construct expression was induced with 100 μM IPTG at OD~600~ 0.4 for 3 h. Cells were harvested by centrifugation at 8 000 *g* for 3 min and resuspended in lysis buffer (100 mM Tris-HCl pH 7.5, 50 mM NaCl, 10 μM zinc acetate) for cell disruption by sonication. Lysates were clarified of cellular debris by sonication three times at 4 000 *g* for 15 min at 4°C before incubation with 10 μg VgrG2b~C-ter~ or VgrG2b~C-ter~ (E936A) at 37°C for 1 h. Ultracentrifugation at 100 000 *g* for 1 h at 4°C separated the soluble and membrane fractions, to which Laemmli buffer was added for subsequent SDS-PAGE and immunoblot analysis. Production of MltC, LolB and RcsF was monitored using antibodies against the C-terminal hexahistidine tag, while production of TEM-1 from pET22b was detected using a monoclonal antibody. Densitometry was conducted in FIJI software.

### Bioinformatic and phylogenetic analysis {#sec4.4.16}

Protein sequences were obtained from the non-redundant NCBI database using the BLASTp algorithm, alignments were done in Jalview using MAFTT and sequence logos were generated using the Weblogo server ([@bib21], [@bib50]). The prediction of bacterial lipoprotein signal peptides, type I signal peptides and transmembrane helices was undertaken using LipoP 1.0, SignalP 4.1 and TMHMM server v2.0, respectively ([@bib53], [@bib75]). The search algorithm Jackhmmer (EMBL-EBI) was used to search for homologs of the VgrG2b metallopeptidase domain. Three iterations querying the UniProtKB database were conducted, retrieving 240 sequences. Sequences were aligned and MEGA7 was employed for phylogenetic analysis, using the maximum-likelihood method of tree generation with 1000 bootstrap replicates ([@bib54]).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

The statistical analyses described in this work were conducted using Prism 8.0 software (GraphPad) and the statistical parameters, including sample sizes (where *n* indicates the number of independent biological replicates, technical replicates or bacterial cells), *p* values and statistical tests performed are indicated in the relevant figure legends. The means of biologically independent replicates were compared using the following statistical tests: Student's t test, a one-way ANOVA followed by Dunnett's or Tukey's multiple comparisons tests. The spread is reported with the standard error of the mean (SEM), or by the median and quartiles for pooled single cell analyses.

Data And Code Availability {#sec4.6}
--------------------------

The accession numbers for the crystal structure and diffraction datasets of VgrG2b~C-ter~ reported in this paper are PDB: [6H56](pdb:6H56){#interref60} and Zenodo: 10.5281/zenodo.3246346, respectively.
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